These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28160213)

  • 1. A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
    Ogawa Y; Izutsu K; Kiguchi T; Choi I; Takatsuka Y; Ando K; Suzumiya J;
    Int J Hematol; 2017 May; 105(5):631-637. PubMed ID: 28160213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
    Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
    Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Robak T; Hellmann A; Kloczko J; Loscertales J; Lech-Maranda E; Pagel JM; Mato A; Byrd JC; Awan FT; Hebart H; Garcia-Marco JA; Hill BT; Hallek M; Eisenfeld AJ; Stromatt SC; Jaeger U
    Br J Haematol; 2017 Feb; 176(4):618-628. PubMed ID: 27977057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
    Flinn IW; Panayiotidis P; Afanasyev B; Janssens A; Grosicki S; Homenda W; Smolej L; Kuliczkowski K; Doubek M; Domnikova N; West SL; Chang CN; Barker AM; Gupta IV; Wright OJ; Offner F
    Am J Hematol; 2016 Sep; 91(9):900-6. PubMed ID: 27222473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
    Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
    Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Hoy SM
    Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
    Wołowiec D; Szymczyk A; Potoczek S; Krochmalczyk D; Zawirska D; Piotrowska M; Malenda A; Soroka-Wojtaszko M; Kopacz A; Wąsik-Szczepanek E; Graboś-Michalak J; Raźny M; Wichary R; Bramowicz-Jarosz B; Seweryn M; Długosz-Danecka M; Hus I
    Chemotherapy; 2019; 64(3):155-162. PubMed ID: 31715597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.
    Kath R; Blumenstengel K; Fricke HJ; Höffken K
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):48-54. PubMed ID: 11206271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
    Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
    Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
    Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
    Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.